The Mortality from Hereditary Angioedema Worldwide: a Review of the Real-World Data Literature

Clin Rev Allergy Immunol. 2022 Feb;62(1):232-239. doi: 10.1007/s12016-021-08897-8. Epub 2021 Oct 23.

Abstract

This study aims to review the global mortality secondary to laryngeal edema in patients diagnosed with hereditary angioedema and their relatives over the years, as well as to describe epidemiological and clinical findings associated with this outcome. An extensive search of the literature was made in PubMed, Scopus, and Embase to identify mortality rates secondary to laryngeal edema in patients with hereditary angioedema. The search was carried out in September of 2020 and in April of 2021, and keywords based on the MeSH terms were searched in three databases. The filter of language was used for finding only articles in English, and there was no limit to the year of publication. A total of twenty-three articles fulfilled the inclusion criteria for review and data extraction. The analyzed studies included 3292 patients and 411 deaths from asphyxia due to laryngeal edema. One hundred and three deaths in close relatives were described as secondary to the same cause. The main findings were summarized in tables: year and place of publication, the number of patients and deaths from laryngeal edema, patients previously diagnosed, and death age. Death rates from laryngeal edema had an average of one death for every 20 patients. Eight studies reported deaths in relatives. For every 7.4 patients in these studies, one relative died. The percentage among deaths in general associated with laryngeal edema was evaluated in three studies (32.7%, 44.4%, and 56%). The high frequency of this outcome suggests that deaths still occur, and improvement of hereditary angioedema treatment still needs to be met.

Keywords: Asphyxiation; C1 inhibitor deficiency; Hereditary angioedema; Laryngeal edema; Mortality.

Publication types

  • Review

MeSH terms

  • Angioedemas, Hereditary* / drug therapy
  • Angioedemas, Hereditary* / epidemiology
  • Complement C1 Inactivator Proteins
  • Complement C1 Inhibitor Protein / therapeutic use
  • Humans
  • Laryngeal Edema* / drug therapy
  • Laryngeal Edema* / etiology

Substances

  • Complement C1 Inactivator Proteins
  • Complement C1 Inhibitor Protein